Arcus Biosciences, Inc. RCUS
18.28 USD +0.59 (+3.34%)
At closeNov 6, 2026, 4:00 PM EST
18.28 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
17.69 Day range 18.50
17.69 52-week range 31.57
- YTD
- -23.29%
- 1 year
- -6.54%
News
benzinga.com Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49 Leerink Partners analyst Daina Graybosch maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $46 to $49.
benzinga.com Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40 Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $41 to $40.
benzinga.com Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45 Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and lowers the price target from $49 to $45.
zacks.com Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.27 per share a year ago.
benzinga.com Arcus Biosciences Q3 EPS $(1.00) Misses $(0.90) Estimate, Sales $9.000M Beat $8.305M Estimate Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.90) by 11.11 percent. This is a 21.26 percent increase over losses of…
businesswire.com Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for…
businesswire.com Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics…- benzinga.com Arcus Biosciences Commences Public Offering of Common Stock; Size Not Disclosed Arcus Biosciences, Inc. (NYSE:RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune…
benzinga.com Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50 Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.- benzinga.com Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41 Truist Securities analyst Supawat Thongthip maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $40 to $41.
benzinga.com Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49 Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $43 to $49.
benzinga.com Arcus Biosciences Reports Casdatifan Kidney Cancer Data, With Nearly 3-Year Median Overall Survival In Heavily Pretreated Patients And Phase 3 Trials Remain Pending Progression-free survival (PFS) for casdatifan plus anti-PD-1 in the first-line (1L) setting exceeded third-party benchmarks* for the approved anti-PD-1 plus anti-CTLA-4 regimen (ipilimumab plus…- benzinga.com William Blair Initiates Coverage On Arcus Biosciences with Outperform Rating William Blair analyst Alethia Young initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Outperform rating.
- benzinga.com JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41 JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.
- benzinga.com Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $43 price target.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics…
- benzinga.com Truist Securities Reiterates Buy on Arcus Biosciences, Raises Price Target to $40 Truist Securities analyst Supawat Thongthip reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $35 to $40.
- benzinga.com Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26 Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.
- benzinga.com Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43 Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.
- benzinga.com Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.87) by 17.24 percent. This is a Infinity percent decrease over earnings…
benzinga.com Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026 This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor…- benzinga.com Arcus Biosciences And Summit Therapeutics Announced A Clinical Trial Collaboration To Evaluate The Safety And Efficacy Of Arcus’s Casdatifan; Data Expected to Be Generated By Mid-2027 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and…
benzinga.com Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%? HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casdatifan in first-line ccRCC.- benzinga.com HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45 HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $32 to $45.
- benzinga.com Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney Cancer This is the first study to comprehensively interconnect clinical outcomes from patients receiving a HIF-2a inhibitor with peripheral biomarker changes and associated tumor biologyHIF-2a inhibition…
- benzinga.com Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdatifan, Its Investigational Small-Molecule HIF-2a Inhibitor Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com Semtech Posts Mixed Q3 Results, Joins Zhihu, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket 
benzinga.com Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday - benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com Earnings Scheduled For May 6, 2025 - benzinga.com Earnings Scheduled For February 25, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- benzinga.com Earnings Scheduled For February 21, 2024 Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
- benzinga.com Earnings Scheduled For November 7, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 369 companies hit new 52-week lows.
- benzinga.com Why Grab Holdings Are Trading Higher By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers AgileThought, Inc. (NASDAQ: AGIL) jumped 85.5% to $0.3941. AgileThought recently posted a loss for the second quarter.
- benzinga.com Earnings Scheduled For August 7, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report quarterly loss at $0.44 per share on revenue of $153.69 million.
benzinga.com Earnings Scheduled For May 9, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 497 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For February 28, 2023 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
- benzinga.com Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who…
- benzinga.com Earnings Scheduled For August 3, 2022 Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report quarterly earnings at $0.79 per share on revenue of $1.15 billion.